IPRIPR2023-00724Terminated-Settled
Mylan Pharmaceuticals Inc. et al.v.Novo Nordisk A/S
IPR challenge of US 10335462.
Type
IPR
Filed
Mar 16, 2023
Instituted
Oct 4, 2023
Decided
Jan 10, 2025
Patent
Application
15656042
Inventor
Christine Bjoern Jensen
Granted
Jul 2, 2019
01
Timeline
3 milestones
2023-03-16Petition filed
2023-10-04Institution
2025-01-10Terminated
02
Parties & counsel
Petitioner
Mylan Pharmaceuticals Inc. et al.
Counsel
White, Brandonet al
Patent Owner
Novo Nordisk A/S
Counsel
Baughman, Jonet al
03
Docket
Documents are mirrored from the PTAB e-file system. Filer is as stated on the face of the filing.
SOURCE · USPTO PTAB E2EView on Unified Patents →